| Literature DB >> 32762697 |
Chanakan Areewong1,2, Amarin Rittipornlertrak1, Boondarika Nambooppha1, Itsarapan Fhaikrue1, Tawatchai Singhla1, Chollada Sodarat1, Worapat Prachasilchai1, Preeyanat Vongchan3, Nattawooti Sthitmatee4,5,6.
Abstract
BACKGROUND: Feline panleukopenia virus (FPV) is an etiologic pathogen of feline panleukopenia that infects all members of Felidae including tigers (Panthera tigris). Vaccinations against FPV among wild felid species have long been practiced in zoos worldwide. However, few studies have assessed the tiger immune response post-vaccination due to the absence of a serological diagnostic tool. To address these limitations, this study aimed to develop an in-house indirect enzyme-linked immunosorbent assay (ELISA) for the monitoring of tiger antibody levels against the feline panleukopenia vaccine by employing the synthesized subunit capsid protein VP2. An in-house horseradish peroxidase (HRP) conjugated rabbit anti-tiger immunoglobulin G (IgG) polyclonal antibody (HRP-anti-tiger IgG) was produced in this study and employed in the assay. It was then compared to a commercial HRP-conjugated goat anti-cat IgG (HRP-anti-cat IgG). Sensitivity and specificity were evaluated using the Bayesian model with preferential conditional dependence between HRP-conjugated antibody-based ELISAs and hemagglutination-inhibition (HI) tests.Entities:
Keywords: Bayesian model; Capsid protein VP2; Feline panleukopenia virus; Hemagglutination inhibition assay; Indirect ELISA; Tiger (Panthera tigris)
Mesh:
Substances:
Year: 2020 PMID: 32762697 PMCID: PMC7409676 DOI: 10.1186/s12917-020-02496-z
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Fig. 1Western blot analysis of binding capability of HRP-conjugated IgG antibody against Bengal tiger IgG. Lane M: Protein marker; Lane 1: HRP-conjugated goat anti-cat antibody, Lane 2: HRP-conjugated rabbit anti-tiger IgG antibody
Optimal serum dilution and HRP-conjugated antibody dilution reacted with 1 ng/100 μl of coating buffer
| HRP-Conjugated antibody | Serum dilution / HRP dilution | S/N ratio | ||||
|---|---|---|---|---|---|---|
| 1:100 | 1:200 | 1:300 | 1:400 | 1:500 | ||
| Anti-cat | 1:1000 | 2.460 | 3.508 | 3.679 | 3.951 | |
| 1:2000 | 2.310 | 2.724 | 2.921 | 3.085 | 3.122 | |
| 1:3000 | 2.350 | 2.641 | 2.959 | 2.949 | 2.983 | |
| 1:4000 | 2.300 | 2.730 | 2.749 | 2.733 | 2.826 | |
| Anti-tiger | 1:1000 | 3.812 | 2.736 | 2.651 | 2.235 | 1.949 |
| 1:2000 | 2.600 | 2.134 | 1.825 | 1.732 | ||
| 1:3000 | 2.577 | 2.132 | 1.968 | 1.649 | 1.603 | |
| 1:4000 | 2.651 | 2.283 | 2.000 | 1.582 | 1.637 | |
a Represents suitable S/N ratio obtained from this study
Comparison of indirect ELISA test and HI test to evaluate the seroprevalence against FPV vaccine
| Diagnostic tests | HI positive | HI negative | Total | ||
|---|---|---|---|---|---|
| ELISA anti-cat positive | ELISA anti-cat negative | ELISA anti-cat positive | ELISA anti-cat negative | ||
| ELISA anti-tiger positive | 164 | 1 | 32 | 1 | 198 |
| ELISA anti-tiger negative | 1 | 12 | 0 | 10 | 23 |
| Total | 165 | 13 | 32 | 11 | |
Posterior estimates for sensitivity and specificity of indirect ELISA and HI tests, and the prevalence
| Diagnostic tests | Parameters | Posterior estimates | |
|---|---|---|---|
| Median (%) | 95% PPIa | ||
| Prevalence | 94.6 | 87.6–98.4 | |
| ELISA (anti-cat) | Sensitivity | 86.7 | 82.0–90.8 |
| Specificity | 64.6 | 47.5–80.0 | |
| ELISA (anti-tiger) | Sensitivity | 86.5 | 81.8–90.8 |
| Specificity | 57.2 | 41.7–71.8 | |
| HI | Sensitivity | 79.1 | 73.4–84.5 |
| Specificity | 54.1 | 30.0–76.2 | |
a95% PPI 95% posterior probability interval
Prior values used for analysis in this study
| Diagnostic tests | Parameters | Prior values | |
|---|---|---|---|
| Mode (%) | 95% CIa | ||
| Prevalence | 50 | < 80 | |
| ELISA (anti-cat) | Sensitivity | 75 | > 63 |
| Specificity | 66 | > 50 | |
| ELISA (anti-tiger) | Sensitivity | 68 | > 53 |
| Specificity | 57 | > 43 | |
| HI | Sensitivity | 56 | > 40 |
| Specificity | 50 | > 30 | |
a95% CI 95% confidence interval